DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study of a New Dressing for Use With Topical Medications

Information source: Teikoku Pharma USA
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Psoriasis

Intervention: Occlusive dressing (Device)

Phase: N/A

Status: Completed

Sponsored by: Teikoku Pharma USA

Official(s) and/or principal investigator(s):
John Koo, MD, Principal Investigator, Affiliation: University of California, San Francisco


The purpose of this study is to determine if a new dressing designed to be used with topical medications will enhance the effects of these topical medications.

Clinical Details

Official title: An Open-Label, Bilaterally-Controlled Single Center Study to Compare the Efficacy of Occlusion of Topical Agents With a Hydrophilic Occlusive Dressing to Treatment With Occlusive Dressing Without the Addition of Topical Agents

Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Efficacy of topical medications with new occlusive dressing at baseline, weeks 2, 4, 6, 8.

Secondary outcome: Efficacy with new occlusive dressing alone without topical medications at baseline, weeks 2, 4, 6, 8.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Subject has signed the informed consent form and HIPAA authorization form

- Male or female subject at least 18 years of age

- A diagnosis of stable plaque-type psoriasis vulgaris with at least one "mirror image"

pair of symmetric lesions on either the trunk, arms, or legs that would serve as target lesions. Paired target lesions must be in similar anatomic locations (e. g., right and left elbows or right and left knees) and have roughly equal (no more than one point difference) modified PASI scores. Both paired target lesions must have PASI scores equal to or greater than 1. 5

- Any additional diagnoses must, in the investigator's opinion, not preclude the

subject from safely participating in this study or interfere with the evaluation of the subject's psoriasis

- Psoriasis must be clinically stable for at least 30 days before enrollment

- Subject is able to completely discontinue the use of any medication or therapy for

relief of psoriasis in the target areas to be treated

- Subject is able to completely discontinue the use of any systemic medication or

therapy (e. g. oral or injectable psoriasis medications, PUVA phototherapy, herbal remedies, or acupuncture) for relief of psoriasis

- Female subjects must be postmenopausal (defined as one year without menses),

physically incapable of becoming pregnant, or using an acceptable birth control method. Acceptable methods of birth control include hormonal contraceptives or double-barrier methods (condom, diaphragm with spermicidal agent or IUD). If practicing an acceptable method of birth control, the subject must have confirmation of a negative urine pregnancy test at Screening

- Subject must be reliable and mentally competent to complete study measurements

- Subject is able to understand and agrees to comply with study requirements, attend

study visits, and comply with the restrictions during the study. Exclusion Criteria:

- Subject has a skin disorder other than psoriasis in the target areas to be evaluated

- Known hypersensitivity to any component of the test medications

- Pigmentation, extensive scarring, or pigmented lesions in affected areas that would

interfere with evaluation of efficacy parameters

- Clinically infected psoriasis at baseline

- Subject is pregnant or nursing

- Guttate, pustular, erythrodermic, or other non-plaque forms of psoriasis

- Spontaneously worsening or improving psoriasis within 30 days of enrollment

- Any evidence of atrophy in the areas selected for treatment with topical


- History of treating potential target lesions differently from one another

- Topical or intralesional therapies (other than emollients) or UVB phototherapy on

potential target lesions within two weeks of starting study treatment

- Systemic therapy, PUVA phototherapy, or a systemic investigational therapy for

psoriasis within 30 days prior to study entry

- Treatment with topical investigational therapy of the target lesions within 30 days

prior to study entry

- Subject is considered unreliable as to medication compliance or adherence to

scheduled appointments as determined by the investigators.

Locations and Contacts

UCSF Psoriasis and Skin Treatment Center, San Francisco, California 94118, United States
Additional Information

Starting date: September 2005
Last updated: June 30, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017